VISCHER’s advised Genedata on the deal. Genedata AG, a leading provider of software solutions for biopharmaceutical R&D, has been acquired by Danaher Corporation (NYSE: DHR), a...
You must be a Standard 1 Year member to access this content.
VISCHER advised Ysios Capital and Kurma Partners. Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
You must be a Standard 1 Year member to access this content.
VISCHER advised Medartis on the deal. Medartis (SIX: MED), a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private...
You must be a Standard 1 Year member to access this content.
Vischer advised Resistell AG on the deal. Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another...
You must be a Standard 1 Year member to access this content.
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
You must be a Standard 1 Year member to access this content.
VISCHER advised EBL on the deal. Swiss full-service provider Sunrise has signed an agreement to acquire the telecom business of utility firm EBL. EBL has been...
You must be a Standard 1 Year member to access this content.
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Novaremed on the deal. Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
You must be a Standard 1 Year member to access this content.
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
You must be a Standard 1 Year member to access this content.
